AI assistant
Sending…
REPLIGEN CORP — Director's Dealing 2024
Jun 14, 2024
30826_dirs_2024-06-14_5d83ecbf-6d18-49f7-826d-6d5e804cab3b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2024-06-14
Reporting Person: DAWES KAREN A (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-14 | Common Stock | M | 2953 | $67.71 | Acquired | 88170 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-14 | Stock Option (Right to Buy) | $67.71 | M | 2953 | Acquired | 2029-05-15 | Common Stock (2953) | Direct |
Footnotes
F1: This option is fully vested and exercisable.
More from REPLIGEN CORP
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 27
Annual Report
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23